Finance & Pricing Archives | Report Store

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

Leading pharmaceutical executives called to testify before a Senate Finance Committee hearing on drug prices were likely the first of many to be summoned. It’s a no-win situation, but preparation can help. Find out why changing the subject can be a smart tactic. Discover how some senators may try to lure execs into inadvertently lying–and learn how to avoid it.

Finance & Pricing

Finance & Pricing

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing

Innovations In Market Access: The Will, But Not The Way?

Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing

Annuity Payment Model For Cures May Get Test Drive In Massachusetts

No More Rebates: HHS Proposed Rule Revises AntiKickback Safe Harbor

US FDA’s Shutdown Offers One Possible Winner

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says

Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change

Part B Payment Model Indexing Commercial Discounts Proposed By Genentech

Eight Things To Know From Novartis’ Third Quarter Call

Cell And Gene Therapies Test New Waters In Pricing And Reimbursement